Abstract: A process for shaping, by compaction, a fibrous structure obtained by three-dimensional or multilayer weaving between a plurality of layers of warp yarns and a plurality of layers of weft yarns. The yarns of each plurality of layers of warp yarns and layers of weft yarns are coated with a sizing composition. The shaping includes a pre-compaction stage followed by a stage of final compaction of the fibrous structure. During pre-compaction and final compaction, the fibrous structure is at a temperature greater than or equal to the softening temperature of the sizing composition. The process further includes the cooling of the fibrous preform obtained after final compaction of the fibrous structure.

Abstract: Methods for manufacturing a turbomachine composite part, such as a fan blade, are provided. The composite part has a fibrous structure with a three-dimensional fibrous preform coated with a surface fibrous web, and which is embedded in a polymer matrix The methods include: forming the surface web in a cavity of a mold in order to shape it, wetting and forming the preform on the surface web in order to shape it, and closing the mold, drying the fibrous structure, and injecting thermosetting resin into the mold in order to form said polymer matrix. The surface web is wetted before and/or during the forming thereof.

Abstract: Methods for manufacturing a turbomachine composite part, such as a fan blade, are provided. The composite part has a fibrous structure with a three-dimensional fibrous preform coated with a surface fibrous web, and which is embedded in a polymer matrix The methods include: forming the surface web in a cavity of a mold in order to shape it, wetting and forming the preform on the surface web in order to shape it, and closing the mold, drying the fibrous structure, and injecting thermosetting resin into the mold in order to form said polymer matrix. The surface web is wetted before and/or during the forming thereof.

Abstract: A process for shaping, by compaction, a fibrous structure obtained by three-dimensional or multilayer weaving between a plurality of layers of warp yarns and a plurality of layers of weft yarns. The yarns of each plurality of layers of warp yarns and layers of weft yarns are coated with a sizing composition. The shaping includes a pre-compaction stage followed by a stage of final compaction of the fibrous structure. During pre-compaction and final compaction, the fibrous structure is at a temperature greater than or equal to the softening temperature of the sizing composition. The process further includes the cooling of the fibrous preform obtained after final compaction of the fibrous structure.

Abstract: A non-invasive method for determining the tissue perfusion state in a patient, by measuring the variations in the skin CO2 pressure and in the perfusion index of the patient during the conducting of a localized hyperthermia test.

Abstract: The present invention pertains to a method for in vitro diagnosing a bacterial infection in a biological fluid selected amongst cerebrospinal fluid, ascitic fluid, pericardial fluid, pleural fluid, urine and synovial fluid, based on the measure, in a sample of said fluid, of the production of reactive oxygen species (ROS); a high level of ROS production is indicative of the presence of activated polymorphonuclear neutrophils (PMNs) in said fluid, which in turn is a hallmark of bacterial infection.

Abstract: A non-invasive method for determining the tissue perfusion state in a patient, by measuring the variations in the skin CO2 pressure and in the perfusion index of the patient during the conducting of a localized hyperthermia test.

Abstract: Novel prognosis methods associated with cases of postpartum haemorrhage providing a predictive test enabling practitioners to provide better management of patients suffering from postpartum haemorrhage. Different risk factors exist on which a score allowing prediction of the need to carry out invasive procedures to stop bleeding has been developed.

Abstract: The present invention relates to an in vitro method of prognosis for the arrest of bleeding in a patient suffering from postpartum haemorrhage in the absence of an invasive procedure, comprising the following steps: (a) determining, using a biological sample from said patient, the plasma fibrinogen concentration, the blood troponin concentration and also the prothrombin time; (b) studying at least two clinical markers for said patient, selected from the group comprising heart rate and the presence of placentation abnormalities; (c) calculating a score Z according to the following equation: Z=a+b+v+d+e; where a is associated with the existence of placentation abnormalities in said patient, with a being 0 when no placentation abnormality is observed in said patient and a being 1 when one or more placentation abnormalities are observed in said patient; where b is associated with the heart rate of said patient, with b being 0 when the heart rate of said patient is less than or equal to 115 bpm (beats per minute)

Abstract: The present invention pertains to a method for in vitro diagnosing a bacterial infection in a biological fluid selected amongst cerebrospinal fluid, ascitic fluid, pericardial fluid, pleural fluid, urine and synovial fluid, based on the measure, in a sample of said fluid, of the production of reactive oxygen species (ROS); a high level of ROS production is indicative of the presence of activated polymorphonuclear neutrophils (PMNs) in said fluid, which in turn is a hallmark of bacterial infection.

Abstract: The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis.

Abstract: The present invention pertains to a non-invasive way of assessing tissue perfusion in a patient, especially for treatment follow-up and prognosis of septic shock. More specifically, tissue perfusion is assessed by measuring the cutaneous partial pressure of carbon dioxide of said patient, for example at ear lobe with a PCO2 sensor which is not heated at a temperature superior to 37.5° C., and by calculating the difference between said cutaneous PCO2 and either the arterial or the end-tidal partial pressure of CO2. A device for performing a continuous non-invasive perfusion follow-up is also part of the invention.

Abstract: The present invention provides methods and kits to obtain an early evaluation of mortality risk and help therapeutic decisions for patients in severe sepsis with two organ failures, for example for patients in septic shock. The invention is based on the measure of the level of S100A8/A9 complex in plasma, since a level of S100A8/A9 above a predetermined threshold is indicative of a bad prognosis and a level of S100A8/A9 below said predetermined threshold is indicative of a good prognosis.

Abstract: The present invention relates to the field of treatment of serious medical syndromes such as severe sepsis and septic shock. In particular, the present invention provides methods and kits to obtain an early evaluation of mortality risk and help therapeutic decisions for patients in severe sepsis with two organ failures, for example for patients in septic shock with one additional organ failure. The methods of the invention are based on the analysis of an expression profile of one or several genes selected in the group consisting of HLA-DRB4, FOSB, GPR109B, RBP7, TLR7, IL15, HLA-C, AMFR, LOC96610, IRF5, MGC29506, EDG3, IGLV1-44, IFIT2, IFI44, EPSTI1, TNFRSF17, AREG, THBS1, CTLS1, TFPI, PHACTR2, PFKFB2 and CHIT1.

Abstract: The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis.